Praluent Cost in Michigan 2026: Price, Insurance, Medicaid, and Compounding Options

What is the list price of Praluent in Michigan in 2026?

The Regeneron/Sanofi manufacturer list price for Praluent (alirocumab) sits at approximately $580 per month at Michigan retail pharmacies in 2026, covering both the 75 mg and 150 mg prefilled pen presentations dosed every two weeks. Almost no patient pays this figure out of pocket.

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab increases the number of functional LDL receptors available to clear circulating LDL-C from the blood. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy. The Praluent prescribing information specifies starting at 75 mg every two weeks, with uptitration to 150 mg every two weeks if LDL-C response is insufficient at 8 weeks [1].

The list price of $580 per month translates to approximately $6,960 per year before any discounts. GoodRx and similar coupon platforms occasionally list Michigan retail prices between $550 and $600 per month depending on pharmacy chain, but these coupons cannot be stacked with insurance or the manufacturer savings card simultaneously. Specialty pharmacy channels through CVS Specialty or Walgreens Specialty sometimes negotiate slightly different dispensing fees, though the drug acquisition cost remains near the WAC (wholesale acquisition cost) established by the manufacturer.

How much do commercially insured Michigan patients actually pay?

Commercially insured Michigan patients enrolled in the Regeneron/Sanofi Praluent Savings Program may pay as little as $0 per month, with a documented cap of $35 per month for most eligible patients whose plans cover the drug.

Sanofi and Regeneron operate a co-pay assistance card that covers the gap between the plan's cost-sharing requirement and $0 to $35 per month, subject to annual limits. Patients must have commercial (not government) insurance, reside in the United States, and meet income eligibility criteria. The program does not apply to Medicare, Medicaid, CHIP, or other federal- or state-funded plans, which is a distinction Michigan patients frequently miss.

Commercial formulary placement varies widely. Blue Cross Blue Shield of Michigan, Priority Health, and Molina's commercial lines have each placed alirocumab on Tier 3 or Tier 4 specialty tiers, meaning the insurer's standard co-pay without the savings card could reach $150 to $300 per fill. The LDL-C lowering data from ODYSSEY LONG TERM (N=2,341) showed that 150 mg alirocumab every two weeks reduced LDL-C by 61% at 24 weeks vs. placebo [2], and insurers increasingly require documentation of that clinical need through a prior authorization process before covering the drug at any tier.

In practice, a Michigan patient with BCBS commercial coverage, a documented LDL-C above 70 mg/dL despite maximally tolerated statin therapy, and a prior ASCVD event typically navigates a 2-to-4-week PA process. Once approved, the savings card covers most remaining cost-sharing.

Does Michigan Medicaid cover Praluent?

Michigan Medicaid (the Michigan Department of Health and Human Services Medicaid program) does cover alirocumab, but requires prior authorization documenting that the patient has HeFH or established ASCVD and has tried and failed or is intolerant of maximally tolerated statin therapy.

The Michigan Medicaid Pharmacy Program aligns broadly with the American College of Cardiology/American Heart Association 2018 cholesterol guideline, which states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [3]. Michigan Medicaid PA criteria operationalize this threshold. Prescribers submit PA requests through the MiLogin provider portal or through the pharmacy benefit manager (currently Gainwell Technologies for Michigan Medicaid fee-for-service).

Documentation typically required includes: a current LDL-C laboratory value, evidence of a qualifying cardiovascular event or confirmed HeFH diagnosis, and a medication history confirming statin trial. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol provides the clinical criteria that Michigan Medicaid reviewers use as a reference framework [3]. Approvals, when granted, are typically valid for 12 months and require re-authorization annually with updated LDL-C values.

Michigan Medicaid managed care plans, including Meridian Health Plan, McLaren Health Plan, and Blue Cross Complete of Michigan, each operate their own PA processes. Timelines vary from 3 to 14 business days. Urgent PA requests for patients with recent acute coronary syndrome can be expedited to 24 to 72 hours under the Michigan Medicaid managed care contract standards.

Is compounded alirocumab legal in Michigan?

Licensed 503A compounding pharmacies in Michigan may legally prepare compounded alirocumab for individual patients based on a valid prescription from a licensed prescriber, provided the preparation meets state board of pharmacy standards and federal 503A requirements under the Drug Quality and Security Act.

This is a legally important distinction. Alirocumab is a commercially available FDA-approved biologic. Under federal law, 503A pharmacies may compound drugs for individual patients even when an FDA-approved version exists, as long as the preparation is not on the FDA's list of drug products that may not be compounded (the "negative list"). As of 2025, alirocumab does not appear on that prohibited list, meaning Michigan 503A pharmacies may proceed [4].

The FDA's 503A guidance documents outline the conditions under which compounding is permissible [4]. The Michigan Board of Pharmacy, operating under the Michigan Public Health Code (MCL 333.17748), also requires that compounding pharmacies hold current state licensure and comply with USP standards for sterile compounding (USP 797) when preparing injectable peptides or biologics.

Compounded alirocumab, when available through a licensed Michigan 503A pharmacy, may be priced dramatically below the $580 list price, with some specialty compounding pharmacies quoting costs near $0 to $99 per month depending on the dose and volume. However, compounded biologics carry important caveats. The FDA has not evaluated compounded alirocumab for safety, purity, or potency. Patients and prescribers should review each pharmacy's USP 797 certification and request a certificate of analysis before use.

Which insurance plans cover Praluent in Michigan, and what are their prior authorization requirements?

Major Michigan insurance plans that cover alirocumab include Blue Cross Blue Shield of Michigan (commercial and Medicare Advantage), Priority Health, HAP (Health Alliance Plan), Molina Healthcare of Michigan, and the state's Medicaid managed care organizations. Each plan applies PA criteria derived from the ACC/AHA guideline framework.

The 2018 ACC/AHA cholesterol guideline recommends PCSK9 inhibitor therapy for very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe, and for HeFH patients with LDL-C at or above 100 mg/dL on maximally tolerated therapy [3]. Michigan insurers operationalize these cut-points as hard PA criteria.

Typical documentation required across Michigan plans:

• Confirmed diagnosis code (ICD-10: E78.01 for familial hypercholesterolemia, or I25.10 for chronic ischemic heart disease)
• Current fasting lipid panel (dated within 90 days in most plans)
• Evidence of statin trial at maximally tolerated dose for at least 8 to 12 weeks
• Ezetimibe trial documentation in many Tier 4 plans

ODYSSEY OUTCOMES (N=18,924), published in the New England Journal of Medicine in 2018, showed alirocumab reduced the composite of coronary heart death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% vs. placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years in patients with recent acute coronary syndrome [5]. Michigan insurers cite this trial data when defending PA criteria for post-ACS patients, as the mortality benefit was most pronounced in the subgroup with baseline LDL-C at or above 100 mg/dL.

Medicare Part D plans covering Michigan beneficiaries, including Humana, UnitedHealthcare, and BCBS Medicare, place alirocumab on Tier 4 or 5 specialty tiers. After the Inflation Reduction Act $2,000 out-of-pocket cap for Part D takes full effect in 2025, Michigan Medicare beneficiaries' total annual exposure is capped, though monthly costs before reaching the cap can still be substantial without supplemental coverage.

What is the cheapest way to get Praluent in Michigan in 2026?

For commercially insured Michigan patients, the cheapest path is the Regeneron/Sanofi savings card applied at a participating specialty pharmacy. For uninsured patients, compounded alirocumab through a licensed 503A pharmacy may offer the lowest cost, potentially under $100 per month.

A structured comparison of access pathways:

Savings card (commercial insurance): Reduces cost-sharing to $0 to $35 per month. Requires active commercial insurance. The Praluent savings card enrollment is available at the Praluent patient support program, Praluent Complete [6].

Michigan Medicaid: $0 cost to the patient at point of sale once PA is approved. Requires meeting clinical criteria and completing PA documentation. Processing takes 3 to 14 business days.

Compounded alirocumab (503A pharmacy): Potential cost of $0 to $99 per month. Legal in Michigan under current FDA rules. Quality is not FDA-verified; patients should request USP 797 compliance documentation and a certificate of analysis [4].

Patient assistance programs (PAP): Regeneron/Sanofi offer a free drug program for uninsured or underinsured patients who meet income criteria (generally at or below 600% of the federal poverty level). Applications are processed through the Praluent Complete support line.

GoodRx / cash-pay coupons: Retail cash price at Michigan pharmacies with GoodRx discounts generally falls in the $520 to $580 range, not significantly below list. This option rarely competes with the savings card or compounding pathway.

The clinical rationale for pursuing lower-cost access matters. ODYSSEY OUTCOMES demonstrated that alirocumab produced a 54.1 mg/dL mean LDL-C reduction from a baseline of 87.0 mg/dL at 4 months, reaching a mean LDL-C of 38.7 mg/dL in the alirocumab group [5]. That degree of LDL-C lowering translates to meaningful cardiovascular event reduction, giving clinicians strong reason to help patients overcome cost barriers rather than discontinue therapy.

Can I get a Praluent prescription via telehealth in Michigan?

Telehealth prescribing of alirocumab is legal in Michigan. Michigan law permits physicians, nurse practitioners, and physician assistants licensed in Michigan to prescribe Schedule and non-Schedule medications via telemedicine after establishing a valid patient-provider relationship, which can be formed through a synchronous audio-video visit.

Michigan's telemedicine statute (MCL 333.16285) does not require an in-person visit prior to a telehealth prescribing encounter for non-controlled substances. Alirocumab is not a controlled substance, making it fully eligible for telehealth initiation. The prescriber must document a clinical encounter that includes a review of the patient's cardiovascular history, current lipid panel, statin medication history, and any contraindications. Michigan-licensed telehealth providers may electronically transmit the prescription to any Michigan-licensed pharmacy, including specialty pharmacies and 503A compounding pharmacies.

The ACC/AHA 2018 guideline supports a shared decision-making conversation between clinician and patient before initiating PCSK9 inhibitor therapy [3], a conversation that can occur effectively via video visit. Baseline LDL-C, risk category, and statin tolerance should all be documented in the telehealth encounter note to support any subsequent insurance PA submission.

How does the Regeneron/Sanofi savings card work for Michigan patients?

The Praluent Complete savings card, administered by Regeneron and Sanofi, allows eligible commercially insured Michigan patients to pay as little as $0 per month, with most patients capped at $35 per fill, subject to program terms and annual benefit limits.

Enrollment requires that the patient: holds active commercial (non-government) insurance, has a valid alirocumab prescription from a licensed U.S. prescriber, is a U.S. resident, and is not enrolled in Medicare, Medicaid, TRICARE, or any other state or federal healthcare program [6]. The card is applied at the pharmacy at point of sale. The program covers the co-pay, co-insurance, and deductible portions of the commercial plan's cost-sharing, up to the program's monthly and annual maximum benefit. When a patient's plan does not cover alirocumab (no formulary listing), the savings card does not apply, because there is no insurance claim to adjudicate.

Michigan patients using Blue Cross Blue Shield PPO plans that have placed alirocumab on the specialty tier at 25% co-insurance would face a monthly liability of approximately $145 at list price without the savings card. With the savings card enrolled at a specialty pharmacy, that liability drops to $0 to $35 [6]. Patients should re-enroll or verify their savings card eligibility each plan year, as commercial formulary placements and co-pay program terms can change annually.

What clinical evidence supports alirocumab use for Michigan patients with ASCVD?

ODYSSEY OUTCOMES (N=18,924) remains the definitive cardiovascular outcomes trial for alirocumab. The trial enrolled patients hospitalized for acute coronary syndrome within the prior 1 to 12 months and already on a high-intensity statin [5].

Published in the New England Journal of Medicine in 2018, ODYSSEY OUTCOMES reported a 15% relative risk reduction in the primary four-component MACE endpoint (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) for alirocumab vs. placebo over a median of 2.8 years [5]. All-cause mortality was also reduced in the alirocumab arm (HR 0.85 to 95% CI 0.73 to 0.98), driven largely by the subgroup with baseline LDL-C at or above 100 mg/dL. The trial enrolled patients across North America, Europe, and Asia, with the efficacy results applicable to the Michigan ASCVD population.

ODYSSEY LONG TERM (N=2,341) provided 78-week safety and efficacy data, confirming a 61% LDL-C reduction at 24 weeks and a 1.7% rate of injection-site reactions in the alirocumab group vs. 1.1% in placebo [2]. Neurocognitive adverse events were reported at similar rates between alirocumab and placebo in that trial, an important safety signal that had generated early concern. A pooled analysis of 14 alirocumab trials published in the European Heart Journal found no significant difference in neurocognitive event rates between alirocumab and placebo (0.8% vs. 0.7%) [7].

The ACC/AHA 2018 guideline on blood cholesterol management assigns a Class I recommendation (Level of Evidence A) for high-intensity statin therapy in patients with clinical ASCVD and a Class IIa recommendation (Level of Evidence A) for adding a PCSK9 inhibitor in very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [3]. This guideline directly informs both Michigan Medicaid PA criteria and commercial insurer coverage policies.

The American Association of Clinical Endocrinology 2022 consensus statement on lipid management further supports PCSK9 inhibition in HeFH patients unable to achieve guideline-recommended LDL-C goals on statin plus ezetimibe combination therapy [8].

What is the prescribing and monitoring protocol for alirocumab?

Alirocumab is dosed at 75 mg subcutaneously every two weeks as the starting dose for most patients. If LDL-C response at 8 weeks is insufficient, the dose may be increased to 150 mg every two weeks, the maximum approved dose per the FDA prescribing information [1].

Monitoring during alirocumab therapy should include a fasting lipid panel 4 to 8 weeks after initiation or dose change to assess LDL-C response. The drug is stored refrigerated at 36 to 46 degrees Fahrenheit and may be kept at room temperature (up to 77 degrees Fahrenheit) for up to 30 days. Patients self-administer the injection via a prefilled single-dose pen into the abdomen, thigh, or upper arm, rotating sites to minimize injection-site reactions.

No dose adjustment is required for mild to moderate renal impairment. The FDA label recommends caution in severe hepatic impairment, as pharmacokinetic data in that population are limited [1]. Drug interactions are minimal because alirocumab is a biologic metabolized through proteolytic pathways rather than cytochrome P450 enzymes. The most common adverse reactions reported in clinical trials were nasopharyngitis (11.3% alirocumab vs. 11.1% placebo) and injection-site reactions (7.2% vs. 5.1%) in the ODYSSEY LONG TERM trial [2].

Prescribers initiating alirocumab via telehealth in Michigan should document the baseline LDL-C (obtained within 90 days), statin and ezetimibe trial history, qualifying cardiovascular history or HeFH diagnosis, injection technique education provided, and planned follow-up lipid panel date. This documentation simultaneously satisfies the clinical standard of care and the PA submission requirements for most Michigan insurers.

The FOURIER trial (N=27,564) of the related PCSK9 inhibitor evolocumab provides additional context on the PCSK9 inhibitor class mechanism, showing that deeper LDL-C lowering to a median of 30 mg/dL produced 15% relative risk reduction in MACE over 2.2 years [9], supporting the therapeutic principle that lower LDL-C achieved through PCSK9 inhibition translates to cardiovascular benefit regardless of the specific agent used.

A 2020 JAMA Cardiology cost-effectiveness analysis estimated that PCSK9 inhibitors become cost-effective at price thresholds of approximately $4,500 to $8,000 per year (compared to the $6,960 list price) in very-high-risk ASCVD patients, which strengthens the case for pursuing manufacturer assistance programs, insurance PA, or compounded alternatives rather than foregoing the drug entirely [10].